MedTrace Logo

Protective Mechanisms Against a Pandemic Respiratory Virus (SLVP024)

NCT03023683 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2021-10-18

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to investigate and compare the human immune response in epithelial cells of the nasopharyngeal mucosa and in blood to live, attenuated influenza vaccine (LAIV) in adults and in children.

Conditions

Interventions

BIOLOGICAL

FluMist®

Influenza Virus Vaccine Live, Intranasal Spray

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Stanford University

    lead OTHER

Principal Investigators

  • Cornelia Dekker, MD · Stanford University

  • Harry Greenberg, MD · Stanford University

  • Xiaosong He, PhD · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2012-11-30
Completion
2012-11-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03023683 on ClinicalTrials.gov